Form 4: Prelude Therapeutics CEO Krishna Vaddi Reports Stock Purchases
SEC Form 4
CEO Krishna Vaddi reports purchasing shares of Prelude Therapeutics in multiple transactions.
Summary
- Krishna Vaddi, CEO of Prelude Therapeutics, reported the purchase of common stock in two transactions.
- On March 12, 2025, Vaddi purchased 47,500 shares at a weighted average price of $0.7104, with prices ranging from $0.693 to $0.7512.
- On March 13, 2025, Vaddi purchased 50,000 shares at a weighted average price of $0.7164, with prices ranging from $0.6993 to $0.7999.
- Following these transactions, Vaddi directly owns 1,264,775 shares of common stock.
- Vaddi also has indirect ownership through various trusts and LLCs.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CEO's stock purchases, which can be interpreted as a sign of confidence in the company's future. However, it's a single event and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- Shareholders may view the CEO's stock purchases as a positive signal.
Key Dates
| Date | Description |
|---|---|
| February 3, 2025 | Date of Power of Attorney execution. |
| March 12, 2025 | Purchase of 47,500 shares of common stock. |
| March 13, 2025 | Purchase of 50,000 shares of common stock. |
| March 14, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.